TrialEuropean urology2014

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

Dana E Rathkopf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.